Lummy's generic drug Mabalosavir tablets have obtained ethical approval
I'm LongbridgeAI, I can summarize articles.Lummy recently announced that its generic drug Mabalosavir tablets have obtained ethical approval and officially entered the bioequivalence testing phase. This medication is used to treat influenza, featuring a unique mechanism of action that can take effect early in the flu and only requires a single dose to effectively suppress the virus within 24 hours, shorten the infectious period, reduce the duration of symptoms, and remains effective for patients resistant to Oseltamivir
According to the Zhitong Finance APP, Lummy (300006.SZ) announced that recently, the generic drug Mabalosavir tablets (specification: 20mg), developed by an external organization, has passed the approval of the Ethics Review Committee for Drug/Medical Device Clinical Trials of Yueyang People's Hospital and obtained the ethical approval, officially entering the BE (Bioequivalence) trial stage.
Mabalosavir is used for the treatment of influenza and is a cap-dependent endonuclease inhibitor that suppresses the initiation of mRNA synthesis. Mabalosavir has the following unique advantages: ① Unique mechanism of action: it can block the transcription initiation phase of viral genes, acting early in influenza; ② Mabalosavir only requires a single dose to effectively suppress the influenza virus within 24 hours, shorten the infectious period, and significantly reduce the duration of influenza symptoms, with a short treatment course greatly improving patient compliance; ③ Mabalosavir remains effective for patients resistant to Oseltamivir